TPDCo slaps sanction on Rick s Café for Mocha Fest jamaicaobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamaicaobserver.com Daily Mail and Mail on Sunday newspapers.
Apollon Jamaica is again seeing patients at our pre-COVID levels, said Stephen Barnhill.
Apollon Formularies Plc (AQSE:APOL) told investors it has reopened its medical cannabis dispensary and treatment centre in Jamaica following certification for COVID-19 health and safety.
The company, in a statement, noted that Jamaica’s Tourism Product Development Company Ltd (TPDCo), an agent for the government, recently performed a COVID-19 compliance assessment of the facility in Negril. We are very proud of our Jamaican team for successfully passing all requirements leading to this certification,” said Stephen Barnhill, group chief executive.
“Since receiving this government required certification, Apollon Jamaica is again seeing patients at our pre-COVID levels.
Certification of Negril Facility
Apollon Formularies plc (AQSE: APOL, Apollon or the Company ) is pleased to announce that the facility and operation located in Negril,
Jamaica, of Apollon Formularies Jamaica Limited ( Apollon Jamaica ), where the medical cannabis dispensary and treatment centre are situated, has passed all requirements and received COVID-19 Health and Safety Protocols Certification and is treating patients.
The Tourism Product Development Company Ltd. (TPDCo), an agent for the Government of Jamaica, recently performed a COVID-19 compliance assessment that involved the health and safety of the Negril,
Jamaica location where Apollon Jamaica and the adjacent Doc s Place Wellness Centre are operated. A certification of compliance for that location was received through Doc s Place from Ms.
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government s Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica s Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the ass